CRIDANIMOD SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10NO3.Na
Molecular Weight	275.2346
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)CN1C2=C(C=CC=C2)C(=O)C3=C1C=CC=C3

InChI

InChIKey=FQMLTEAEJZVTAJ-UHFFFAOYSA-M

InChI=1S/C15H11NO3.Na/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16;/h1-8H,9H2,(H,17,18);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C15H10NO3
Molecular Weight	252.2448
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02064725 | https://clinicaltrials.gov/ct2/show/NCT03077698

Cridanimod (Virexxa) is a small-molecule immunomodulator and interferon inducer, which, in preliminary studies, has been shown to increase progesterone receptor expression in endometrial tissue. Restoration of progesterone receptor expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Cridanimod was originally developed by Polysan and Pharmsynthez and licensed to Xenetic Biosciences. Virexxa is currently being studied in an ongoing Phase 2 multi-national study in conjunction with progestin therapy for the treatment of endometrial cancer in women with the recurrent or persistent disease who have failed progestin monotherapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
progesterone receptor signaling pathway 2 Target ID: GO:0050847 Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent or persistent endometrial carcinoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02064725	Primary		Phase II 1147	Unknown Approved Use Unknown
Endometrial cancer 44 Sources: https://clinicaltrials.gov/ct2/show/NCT03077698	Primary		Phase II 1147	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP19A1 429 CYP1A2 2153	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 7.0	no [IC50 13.8029 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 170.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 218.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 210.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 208.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 209.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 2.0	yes [IC50 4.5646 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 205 \| 208	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/38072#section=BioAssay-Results Page: 133.0

PubMed

Title	Date	PubMed
[Focal immunophysiotherapy in combined treatment of men with manifestations of papilloma virus infection].	2011-03-25	21427998
[Combined cycloferon treatment of tuberculosis in patients infected with HIV].	2010-07	20821978
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].	2010-04	20486553
[Cycloferon efficacy in viral and bacterial diseases of children (clinical review)].	2010	21574424
[Optimization of prophylaxis of relapses of primary erysipelas with the use of cyclopheron].	2010	21395032
[Use of cycloferon in the treatment of patients with pulmonary tuberculosis with mild clinical manifestations].	2010	21381350
[Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)].	2010	21341470
[The cytokine profile in the acute period of tick-borne neuroinfections in children].	2010	21322819
[Clinical laboratory approaches to parodontitis treatment optimization].	2010	21311440
[Effectiveness of cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis].	2010	21207889
[Optimization of parodontitis treatment of patients with tuberculosis].	2010	21186645
[Changes of functional activity of peripheral blood leukocytes during the immunotherapy of tick-borne infections in children].	2010	21183923
[Cycloferon in complex therapy of chronic brucellosis].	2010	21140564
[The use of cycloferon in the combined treatment of tuberculosis patients infected with HIV and viral hepatitis].	2010	21089459
[Correction of immunity disorders, treatment of intestinal infections and disbiosis in children (clinical review)].	2010	21033474
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].	2010	20695208
[Efficacy of cycloferon in the treatment of brucellosis].	2010	20608067
[Cycloferon efficacy in the treatment of acute respiratory tract viral infection and influenza during the morbidity outbreak in 2009-2010].	2010	20583555
[Parodontitis immunotropic therapy in patients with chronic viral and bacterial infections].	2010	20559229
[Clinical efficiency of the use of interferon inductors in surgical patients].	2010	20559225
[Improvement of parodontitis therapy of patients with HIV-infection].	2010	20517247
[Pathogenetic therapy of tuberculosis of respiratory organs during sanatorium-and-spa treatment].	2009-12-19	20017380
[Improvement of natural resistance in children for prophylaxis of influenza and acute respiratory tract viral infections (results of multicenter randomized trials)].	2009	20415263
[Cycloferon, as an agent in the therapy and urgent prophylaxis of influenza and acute respiratory tract viral infection (multicentre randomized controlled comparative study)].	2009	20201401
[Type 1 and type 2 interferon inductor (cycloferon) in therapy of children with pyelonephritis associated with herpes viruses].	2009	20052918
[Up-to-date approach to treatment of inflammatory infections in the maxillofacial region].	2009	19711852
[Cycloferon in the treatment of infectious diseases].	2008	18942425
[Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].	2008	18942421
[Effect of intranasal aerosol-therapy with cycloferon on the function of respiration in patients with some forms of rhinitis].	2007-01	17327631
Structural, spectroscopic, and magnetic study of bis(9,10-dihydro-9-oxo-10-acridineacetate)bis(imidazole)bis(methanol) nickel(II).	2006-12-25	17173403
[Immunological and microbiological aspects of low intensity laser effect on the factors of local immunity of the reproductive tract in women with chlamydia infection].	2006-09-01	16941885
[Effect of aerosol therapy with cyclopheron in patients with chronic rhinitis].	2006-06	16905806
[Some pathogenic mechanisms of aerozol-therapy including cyclopheron treatment in patients with chronic rhinitis].	2006-05	16783061
[Influence of cycloferon on the biological properties of bacterial intracellular pathogens].	2005-07-21	16028504
[Individual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon].	2005-05-11	15881395
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections].	2005-01-08	15636140
[Cyclopheron pretreatment in opisthorchiasis management in patients with viral hepatitis C].	2005	16404860
[The preclinical diagnosis, prevention and treatment of postoperative iridocyclitis in patients after intraocular aphakia correction].	2004-09-24	15384841
[Neuroimmunopathologic aspects of epilepsy].	2004	15455693
[Cytokinin inducing and antiviral activity of cycloferon on experimental herpetic infection].	2003-09-12	12966893
Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro.	2003-04	12742573
[Use of cycloferon in a combined treatment of chlamydial conjunctivitis].	2003-03-01	12608044
[Treatment of patients with invasive bladder cancer].	2003-02-13	12577575
[Effect of interferon inductors on infection induced by hepatitis C virus and activity of mRNA cytokines in cell cultures SW-13 and MT-4].	2003-01-02	12508677
[Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by cycloferon].	2003	14763254
[Pulmonary surfactant and blood serum in patients with chronic obstructive bronchitis on differentiated therapy].	2002-07-31	12145894
Regulation of cytokine mRNAs by interferon and interferon inducers.	2002-07	12687259
[Cycloferon in treating duodenal ulcers in rats].	2002-03-02	11871237
[Increase in NK-activity using superlow doses of the immunomodulator cycloferon].	2001	11552653
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.	1992-07-24	1495008

Patents

Sample Use Guides

In Vivo Use Guide

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:53:28 GMT 2025` Edited by `admin` on `Mon Mar 31 18:53:28 GMT 2025`
Record UNII	54W868ROLR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CRIDANIMOD SODIUM

Common Name

English

CAMEDON

Preferred Name

English

Cridanimod sodium [WHO-DD]

Common Name

English

NEOVIR

Brand Name

English

SODIUM 9-OXO-10-ACRIDINEACETATE

Systematic Name

English

XBIO-101

Code

English

CAMEDONE

Common Name

English

10(9H)-ACRIDINEACETIC ACID, 9-OXO-, SODIUM SALT (1:1)

Common Name

English

Camedon [WHO-DD]

Common Name

English

Camedon sodium [WHO-DD]

Common Name

English

N-(CARBOXYMETHYL)-9-ACRIDONE SODIUM SALT

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

267508